Compass Therapeutics (CMPX) Reiterated at Buy by Stifel Ahead of April Disclosure

March 31, 2026 7:32 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented, "While ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found